Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

about

Validation of a risk prediction model for Barrett's esophagus in an Australian population.

P2860

Q54949381-95D4C094-0572-45B5-9CE0-46C61CA32E0B

P2860

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

Item

http://www.wikidata.org/entity/Q37542809

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

@en

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview.

@nl

type

Item

label

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

@en

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview.

@nl

prefLabel

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

@en

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview.

@nl

P1476

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

@en

P2093

Nele Schoofs

http://www.w3.org/2001/XMLSchema#string

P2860

BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis

Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

A multibiomarker risk score helps predict risk for Barrett's esophagus.

History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

Is there publication bias in the reporting of cancer risk in Barrett's esophagus?

Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study.

Incidence of adenocarcinoma among patients with Barrett's esophagus.

P304

1-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.20524/AOG.2016.0091

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hans Prenen

Raf Bisschops

P577

2016-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28042232

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5198232

http://www.w3.org/2001/XMLSchema#string

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

about

P2860

P2860

Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932